PRPO

Precipio, Inc. [PRPO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PRPO Stock Summary

Top 10 Correlated ETFs

PRPO

Top 10 Correlated Stocks

PRPO

In the News

PRPO Financial details

Company Rating
-
Market Cap
9.14M
Income
-5.86M
Revenue
14.42M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
51
Optionable
No
Shortable
Yes
Earnings
15 May 2024
P/E
-0.88
Forward P/E
-
PEG
0.16
P/S
0.66
P/B
0.62
P/C
-
P/FCF
-1.55
Quick Ratio
0.56
Current Ratio
0.79
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.89
EPS next Y
-
EPS next Q
-
EPS this Y
-57.97%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-37.29%
Revenue last 5Y
37.19%
Revenue Q/Q
15.81%
EPS Q/Q
-162.5%
-
-
-
-
SMA20
-3.79%
SMA50
-16.21%
SMA100
3.21%
Inst Own
-
Inst Trans
-
ROA
-48%
ROE
-63%
ROC
-0.67%
Gross Margin
37%
Oper. Margin
-73%
Profit Margin
-73%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.752-15.42
52W High
-59.47%
52W Low
+52%
RSI
49.98
Rel Volume
0.51
Avg Volume
6.86K
Volume
3.53K
Perf Week
16.03%
Perf Month
-15.44%
Perf Quarter
-1.14%
Perf Half Y
-4.4%
-
-
-
-
Beta
1.252
-
-
Volatility
0.69%, 0.69%
Prev Close
5.74%
Price
6.08
Change
4.47%

Something similar

Top by Market Cap
LLY.SW
NVDA
CMC.DE
VFINX
FXAIX
Top Correlated ETFs
CNCR
URNM
URA
BBC
GNOM
Top Correlated Stocks
MIND
ITRM
SONN
ENSC
TNLX
Similar Market Cap
KLS.TO
SQZ
WBII
VMAR
QTT

Company Profile

Healthcare Medical - Diagnostics & Research
  • Volume Average 6.86K
  • Market Capitalization 9.14M
  • Employee 51
  • CEO Mr. Ilan Danieli
  • Headquarters New Haven,CT,US
  • IPO Date 2017-06-30
  • Website https://www.precipiodx.com

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.